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Diabetic nephropathy is one of the triad of specific microvascular complications in the eye, kidney and peripheral nerve, 
recognised as such in the 1950s (Root et al, 
1954). The association between diabetic and renal 
abnormalities was known in the 19th Century 
but it was not until the description of nodular 
glomerulosclerosis by Kimmelstiel and Wilson 
in the 1930s that the pathological basis of 
nephropathy was established (Kimmelstiel and 
Wilson, 1936).
Diabetes is the most common single cause of 
end-stage renal failure worldwide and represents 
a major public health problem (Saran et al, 
2015). Early identification and evidence-based 
intervention are critical to prevent development 
and to slow progression.
Pathophysiology 
Although the kidneys are generally enlarged mainly 
owing to tubular hyperplasia, the histological 
appearance at diagnosis of type 1 diabetes is 
essentially normal. The earliest pathological 
abnormality is increased thickening of the 
glomerular capillary basement membrane due to an 
accumulation of matrix material (Osterby, 1992). 
Nearly all people with diabetes will demonstrate 
this abnormality after 10 years. A minority 
will show a steady increase in matrix in the 
areas between the capillaries (the glomerular 
mesangium), which eventually obliterates them 
and reduces the filtration capacity of the kidney, 
ultimately leading to organ failure (Figure 1) 
(Osterby, 1992). This process takes many years and 
the pathological features and clinical course are 
pathognomonic of diabetic nephropathy.
At some stage the capillaries will start to leak 
proteins (initially albumin, but larger molecules as 
nephropathy progresses) and these can be detected 
in the urine. Albuminuria is thus the earliest 
clinical feature of nephropathy (Marshall and 
Flyvbjerg, 2006).
As filtration surface is lost secondary to capillary 
occlusion by matrix material, then glomerular 
filtration rate gradually declines (at rates of 
4–10 mL/min/year) and plasma creatinine and 
urea concentrations start to rise (Marshall and 
Flyvbjerg, 2006). 
Finally, an important clinical correlate is 
systemic blood pressure, which rises as albuminuria 
increases and glomerular filtration declines. High 
blood pressure accelerates the pathological processes 
and is an important target for intervention (Marshall 
and Flyvbjerg, 2006).
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The same processes can be seen in type 2 
diabetes and the pathological features in the 
kidney are broadly the same (White and Bilous, 
2000). However, because the precise onset 
of hyperglycaemia is difficult to determine, 
individuals may have established nephropathy at 
diagnosis of diabetes. Moreover, many will have 
pre-existing vascular disease and hypertension, so 
there may be other causes of renal disease, such as 
ischaemia, and blood pressure may be high before 
diabetes develops. 
Older people (particularly women) may have 
recurrent urinary tract infections, which may 
cause tubulointerstitial damage contributing to 
functional impairment. Thus, the natural history 
of kidney disease in people with type 2 diabetes 
can vary depending on the balance of underlying 
pathological causes (Fioretto et al, 1996). 
Apart from hyperglycaemia and hypertension, 
there are other processes that are thought to 
contribute to nephropathy development (Box 1).
 
Diagnostic tests and staging
Albuminuria
Classically, the diagnosis of nephropathy depended 
upon the detection of proteinuria in a person with 
diabetes. The development of routine urine testing 
dipsticks for protein made diagnosis easier but 
these methods were only sensitive to an albumin 
concentration of around 300 mg/L.
The development of more sensitive assays for 
albumin in the 1980s demonstrated that people 
developing nephropathy had smaller increases in 
albuminuria long before the routine tests were positive. 
This phenomenon was termed “microalbuminuria” 
(not a great term as the albumin is the same but 
just present in smaller amounts) or “incipient 
nephropathy,” but is now called moderately elevated 
albuminuria (NICE, 2014). Traditional dipstick-
positive albuminuria then became known as 
“macroalbuminuria” or overt (sometimes clinical) 
nephropathy, but is now called severely elevated 
albuminuria (NICE, 2014).
Consensus has defined the limits of normal, 
moderate and severe albuminuria based on timed 
urine collections (Royal College of Physicians of 
Edinburgh, 2007; Kidney Disease Outcomes Quality 
Initiative, 2012). However, these are cumbersome for 
individuals to collect and labour intensive to analyse, 
so spot urine samples for albumin corrected for urinary 
concentration of creatinine (the albumin–creatinine 
ratio) have been adopted and diagnostic thresholds 
defined (Table 1). 
It must be remembered that albuminuria is a 
continuous variable, so any cut-off point defining 
disease is slightly arbitrary and there will be false-
positive and negative results, particularly at the 
upper or lower limits of disease or stage classification 
(see Table 2). The situation is further complicated 
because moderate albuminuria can be found: in 
people with hypertension but without diabetes; in the 
presence of urinary tract infections; in people with 
Figure 1. Photomicrograph of 
a glomerulus from a person 
with type 1 diabetes and 
macroalbuminuria. Note the 
thickened and split Bowman’s 
capsule (BC), expansion of the 
mesangial (intercapillary) space 
(MES), thickened glomerular 
basement membrane (GBM) 
and capillary closure (CAP). 
Courtesy of Dr K White, 
Biomedical Electron Microscopy 
Unit, Newcastle University, 
Newcastle Upon Tyne. 
Major factors l Hyperglycaemia 
  l Hypertension 
  l Renal haemodynamics 
  l Genes and ethnicity
Other factors l Mechanical stretch of the glomerular capillary  
   basement membrane 
  l Structural factors 
  l Hyperlipidaemia 
  l Low birth weight 
  l Growth factors 
  l Smoking 
  l Endothelial dysfunction 
  l Dietary protein intake 
  lObesity 
  l Hydrocarbon exposure
Box 1. Potential causative factors for diabetic nephropathy.
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metabolic syndrome; and in ischaemic nephropathy 
or tubulointerstitial disease. It is therefore much less 
specific for nephropathy in type 2 diabetes although 
the presence of retinopathy in people with albuminuria 
makes underlying diabetic glomerulopathy much more 
likely (He et al, 2012). In addition, it is now realised 
that increases, even within the normal range, may 
predict later development of nephropathy (Hovind et 
al, 2004), and there is considerable fluctuation such 
that those with moderate albuminuria may revert 
spontaneously to normal (Perkins et al, 2003). A list 
of the causes of false-positive and false-negative tests is 
shown in Table 1 (see footnote).
Glomerular filtration rate
The detection of albuminuria is the cornerstone 
of diagnosis of nephropathy. However, of 
immediate relevance to the patient and clinician 
is glomerular filtration rate (GFR). 
At diagnosis, GFR can be elevated in people 
with type 1 or 2 diabetes. This is often termed 
“hyperfiltration” and may contribute to later 
nephropathy development. The rate of decline 
of GFR thereafter determines the progression of 
nephropathy and likely timing of end-stage renal 
disease (ESRD) requiring renal replacement 
therapy. As it is important to plan this well in 
advance, then an estimate of GFR is clinically 
important. Precise estimates of GFR can be 
performed using infusions of neutral molecules, 
Urine specimen Moderate (micro) 
albuminuria 
Severe (macro)
albuminuria
Timed overnight collection 20–199 µg/min ≥200 µg/min
24-hour collection 30–299 mg/day ≥300 mg/day
Albumin concentration 20–300 mg/L >300 mg/L
Albumin–creatinine 
ratio (ACR)
Men 2.5–30 mg/mmol 
Women 3.5–30 mg/mmol
>30 mg/mmol 
>30 mg/mmol
NICE (2014) guidance on chronic kidney disease suggests that positive tests for 
microalbuminuria should be confirmed within 3–4 months before making a firm diagnosis 
of nephropathy. False-positive tests can occur after vigorous exercise, in the presence 
of infection or blood (e.g. menses), or with a concentrated urine (less of a problem with 
albumin–creatinine ratio). False-negative tests can occur with a diuresis. Angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker therapy can reduce 
microalbuminuria into the normal range.
Table 1. Classification of diabetic nephropathy by albuminuria (adapted from 
Kidney Disease Outcomes Quality Initiative, 2012).
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Table 2. Stages of CKD and historical definition of DKD.
Albuminuria stage, description and definition
GFR stage, description 
and definition
A1 normal
<3.0 mg/mmol
A2 moderate (micro)
albuminuria 
3.0–30 mg/mmol
A3 severe (macro) albuminuria  
>30 mg/mmol
G1 (normal)
>90 mL/min/1.73 m2
At risk for DKD* Possible DKD
(likely if DR)
Likely DKD especially if DR
(consider other causes of albuminuria in 
type 2 diabetes)
G2 (mild decrease)
60–89 mL/min/1.73 m2
At risk for DKD* Possible DKD
(likely if DR)
Likely DKD especially if DR
(consider other causes of albuminuria in 
type 2 diabetes)
G3a (mild–moderate decrease)
45–59 mL/min/1.73 m2
Possible DKD
(probable if DR)
Likely DKD
(definite if DR)
DKD
G3b (moderate–severe decrease)
30–44 mL/min/1.73 m2
Possible DKD
(probable if DR)
Likely DKD
(definite if DR)
DKD
G4 (severe decrease)
15–29 mL/min/1.73 m2
Possible DKD
(probable if DR)
Probable DKD
(likely if DR)
DKD
G5 (kidney failure)
<15 mL/min/1.73 m2
Likely DKD
(definite if DR)
Probable DKD
(likely if DR)
DKD
*Not CKD unless abnormal urinalysis and/or abnormal renal imaging present. 
CKD=chronic kidney disease; DKD=diabetic kidney disease; DR=diabetic retinopathy.
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such as inulin, and measuring their appearance in 
the urine (Stevens et al, 2006).
Infusion of filtration markers is clearly of 
limited routine utility. Endogenous creatinine, 
however, can serve almost as well. Creatinine is 
produced from muscle cells as part of normal 
metabolism and is completely filtered by the renal 
glomerulus. Under steady-state conditions, its 
production and excretion are in balance and it can 
be used as a filtration marker. A timed (usually 
24-hour) urine collection can thus derive an 
estimate of GFR from creatinine clearance using 
the above formula. This estimate, however, is still 
dependent on a urine collection (Stevens et al, 
2006).
As GFR declines, plasma creatinine 
concentrations will rise, but do not cross the 
upper limit of normal until there is significant 
loss of filtration capacity. In 1999, researchers 
used the patient database from the Modification 
of Diet in Renal Disease (MDRD) study to 
derive an equation that would convert a plasma 
creatinine concentration into an estimate of GFR 
(now called eGFR; Levey et al, 1999; 2009). An 
alternative method called the Cockroft–Gault 
equation also exists but this estimates creatinine 
clearance, not GFR, and requires a measure of 
body weight. The four-point MDRD equation is:
eGFR=175 × (serum creatinine [µmol/L] × 
0.0113)–1.154 × (age [years])–0.203
(multiply by 0.742 if female; multiply by 1.21  
if of African-Caribbean origin)
This estimated GFR has been used as a basis for 
diagnosis and staging of chronic kidney disease (CKD; 
Levey et al, 1999) and has been recently modified 
by the inclusion of grading of albuminuria (Kidney 
Disease Improving Global Outcomes, 2013). Table 3 
is adapted from the NICE (2014) guidelines on CKD 
and is a useful tool for determining the frequency of 
monitoring GFR for people with or at risk of CKD.
Creatinine has its limitations as a marker of 
filtration and this must be borne in mind when 
interpreting eGFR (Box 2). Moreover, eGFR tends to 
underestimate true GFR, particularly at values above 
60 mL/min/1.73 m2. However, eGFR is an important 
way of recognising impairment of renal function at 
low serum creatinine concentrations. 
In addition, large intervention trials in people 
with cardiovascular (CV) disease have shown that 
a reduced eGFR is an independent risk factor for 
morbidity and mortality and this relationship is also 
true for people with diabetes (Anavekar et al, 2004; 
Go et al, 2004). In South Tees, mortality rates were 
twice as high in people with diabetes and an eGFR 
of <30 mL/min/1.73 m2 compared with those with 
a value of >90 mL/min/1.73 m2 (Nag et al, 2007). 
Thus, the detection of a falling eGFR should prompt 
rigorous management of CV disease risk factors. 
Epidemiology
Incidence and prevalence of nephropathy depends 
on the diagnostic criteria and the population under 
study. Using albuminuria, reported transition 
rates from normal to moderate albuminuria are 
around 1–2% per annum and are about the same 
for type 1 and type 2 diabetes (Adler et al, 2003). 
However, these rates can be strongly influenced 
by other factors, such as duration of diabetes, 
ethnicity and presence of hypertension, CV disease 
or obesity. Transition rates from moderate to severe 
albuminuria are slightly higher at approximately 
3% per annum, but this is heavily influenced by the 
baseline albuminuria – the higher this is, the greater 
the rate of transition (ACE Inhibitors in Diabetic 
Nephropathy Trialist Group, 2001). 
Prevalence rates are much more variable and 
dependent on the population under study. In general, 
population-based studies (not confined to secondary 
care) report rates for moderate albuminuria of 
12–27%, and 19–42% for type 1 and type 2 diabetes, 
respectively. For severe albuminuria the reported 
range is even wider at 0.3–24% for type 1 and 9–33% 
for type 2 diabetes (Bilous, 1996). These data refer to 
definitions of nephropathy based upon albuminuria; 
in the USA, the prevalence of CKD (combining 
albuminuria or a reduced GFR or both) in the general 
population with diabetes was around 2.3% for the 
period 2007–2012, up from 1.8% in 1994–1998 
(Saran et al, 2015).
End-stage renal failure is easier to define but 
rates are not linear with duration. Using a national 
disease register, rates of 2.2% and 7.8% for people 
with type 1 diabetes with 20 and 30 years’ duration, 
respectively, have been reported from Finland (Finne 
et al, 2005). For the UKPDS (UK Prospective 
Diabetes Study) cohort of people with newly 
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diagnosed type 2 diabetes, 0.6% of people required 
renal replacement therapy or died from renal failure 
after 10.4 years of known diabetes duration (Adler 
et al, 2003; Bilous, 2008). Latest data from the UK 
Renal Registry for 2013 report an incidence rate of 
25.4 per million population for diabetes as a cause of 
ESRD and a prevalence of 15.9% for those already 
on renal replacement therapy (UK Renal Registry, 
2015).
The main reason for the discrepancy in rates of 
ESRD between type 1 and 2 diabetes is the increased 
CV mortality seen in people with nephropathy 
generally, and those with a reduced eGFR specifically. 
In the UKPDS, mortality was two- to three-fold 
greater in those with moderate or severe albuminuria 
compared with normoalbuminuria. For those 
with a plasma creatinine >175 µmol/L or requiring 
renal replacement therapy, mortality was 14-fold 
greater (Adler et al, 2003). Thus, many people 
with nephropathy are dying before entering ESRD 
requiring renal replacement therapy. 
Encouragingly, recent data from the US 
have suggested that incident rates of diabetic 
ESRD requiring renal replacement therapy 
have been declining since 1996 at around 
3.4%/year/100 000 people with diabetes and this 
is particularly noticeable for type 1 diabetes. The 
reasons are unclear but probably reflect better 
overall diabetes and blood pressure management 
(Burrows et al, 2010) but may also be due to earlier 
detection and diagnosis of diabetes thus increasing 
the denominator and artificially reducing incidence 
rates. Unfortunately, prevalence rates of people with 
diabetes on renal replacement therapy continue to 
rise and now exceed 700 per million population 
with a steady year-on-year increase over the last 
decade (Saran et al, 2015).
Clinical features
There are no specific clinical features of nephropathy 
in its early stages. In people with type 1 diabetes 
a rise in blood pressure is a subtle sign but usually 
accompanies an increase in albuminuria (Marshall 
and Flyvbjerg, 2006). 
The clinical features of established nephropathy 
are often dictated by concomitant comorbidities 
that can be diabetes specific (retinopathy and 
neuropathy) or due to macrovascular disease in the 
coronary, cerebral or peripheral vasculatures. The 
majority of people entering end-stage renal failure 
due to diabetic nephropathy will have evidence of 
some or all of these complications.
In only a minority of people does the proteinuria 
become so great as to lead to the nephrotic 
syndrome of hypoalbuminaemia, peripheral 
oedema, hypercholesterolaemia and heavy 
proteinuria. Such people have a poor prognosis 
from the cardiorenal perspective (Skupien et al, 
2014).
As renal impairment gets worse, anaemia due 
to erythropoietin deficiency is more common 
and is said to occur earlier in people with diabetic 
l Can be increased following vigorous exercise, high-animal-protein meal, 
dehydration or acute kidney injury.
l Progressive kidney function decline leads to proportionally more tubular 
secretion, which over-estimates true glomerular filtration rate (GFR).
l Non-linear relationship with GFR so plasma concentration only increases 
once GFR significantly reduced (a doubling of plasma creatinine roughly 
equates to a halving of GFR).
Box 2. Limitations of plasma creatinine concentration as a marker  
of glomerular filtration.
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ACR categories (mg/mmol) description and range
A1 <3
Normal to mildly 
increased
A2 3–30
Moderately 
increased
A3 >30
Severely 
increased
G
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ge G1 ≥90
Normal and high ≤1 1 ≥1
G2 60–89
Mild reduction related to 
normal range for a young 
adult
≤1 1 ≥1
G3a 45–59
Mild–moderate 
reduction
1 1 2
G3b 30–44
Moderate–severe 
reduction
≤2 2 ≥2
G4 15–29
Severe reduction 2 2 3
G5 <15
Kidney failure 4 ≥4 ≥4
ACR=albumin–creatinine ratio; GFR=glomerular filtration rate.
Table 3. Recommended number of times per year GFR should be monitored 
according to the GFR and ACR stage of the individual, adapted from NICE (2014).
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nephropathy compared with those with non-
diabetic kidney disease for any given GFR (Bosman 
et al, 2001). Prevalence studies suggest that around 
15% of people with diabetes will have a World 
Health Organization-defined anaemia (<12 g/dL in 
premenopausal women; <13 g/dL for men), and these 
rates increase as GFR declines (Jones et al, 2010).
Hyperphosphataemia, hypocalcaemia and 
secondary hyperparathyroidism are also features of 
declining GFR and can lead to osteodystrophy and 
possibly contribute to macrovascular calcification.
As GFR declines towards CKD stage 5, 
symptoms of uraemia such as nausea, anorexia, 
pruritus, bad taste, tiredness and weight loss 
(sometimes masked by increasing peripheral 
oedema) develop. The occurrence of these is a sign 
that renal replacement therapy is imminent.
Management in primary care 
and when to refer 
Tight glycaemic control is the only therapy shown 
to prevent development of moderate albuminuria in 
type 1 diabetes. The DCCT (Diabetes Control and 
Complications Trial) showed an approximately 50% 
reduction in moderate albuminuria after 9 years 
of tight control. This benefit continued for 8 years 
after the study completed despite the fact that 
HbA1c levels were similar in the original intensively 
and conventionally treated cohorts during follow-
up. Even after this duration of study, there was no 
significant impact on the numbers needing renal 
replacement therapy partly because there were 
so few events (DCCT/Epidemiology of Diabetes 
Interventions and Complications [EDIC] Research 
Group, 2003). Latest data from the same group 
have shown fewer individuals developing renal 
impairment (GFR <60 mL/min/1.73 m2) during 
follow-up, but rates of loss of GFR were similar in 
the intensive and conventionally treated groups 
(DCCT/EDIC Research Group, 2011).
For people with type 2 diabetes, the UKPDS 
showed a smaller but still significant reduction in 
incident moderate albuminuria in the intensively 
treated group. In addition, although the numbers 
were very small, fewer people had a doubling of 
their baseline serum creatinine (roughly equivalent 
to a halving of GFR) in the intensive arm (UKPDS 
Group, 1998a). The ACCORD (Ismail-Beigi et al, 
2010) and ADVANCE (ADVANCE Collaborative 
Group, 2008) studies showed some benefit of tight 
glycaemic control on development of albuminuria, 
but meta-analysis has failed to show benefit on 
hard end-points such as ESRD (Hemmingsen et 
al, 2011). Current guidance suggests a target HbA1c 
level of <48 mmol/mol (<6.5%) in people with 
type 1 diabetes (NICE, 2015a). In type 2 diabetes, 
a target HbA1c of 48 mmol/mol (6.5%) in those 
on a diet, with a threshold of escalation of therapy 
at 59 mmol/mol (7.5%), is suggested to prevent 
microvascular complications, but with consideration 
of the risk of hypoglycaemia, particularly in the 
elderly (NICE, 2015b). There is no conclusive 
evidence of an effect of tight glycaemic control on 
nephropathy development once moderate or severe 
albuminuria has developed, but the Joslin clinic 
(USA) has reported an association of slower rates 
of decline of GFR in those with better long-term 
glycaemic control (Skupien et al, 2014). NICE 
recommendations for kidney damage in type 2 
diabetes are outlined in Box 3.
Once moderate or severe albuminuria has 
developed, blood pressure management is critical. 
All patients should be given general advice about 
reducing dietary salt and alcohol, weight reduction 
and increasing exercise. However, most will also 
require drug therapy.
Drugs that block the renin–angiotensin system 
(RAS) have not been consistently shown to prevent 
moderate albuminuria in people with type 1 or 
type 2 diabetes who have well-controlled blood 
l Ask all people with or without detected nephropathy to bring in a first-pass 
morning urine specimen once a year. In the absence of proteinuria or urinary 
tract infection (UTI), send this for laboratory estimation of albumin–creatinine 
ratio (ACR). Request a specimen on a subsequent visit if UTI prevents 
analysis.
l Make the measurement on a spot sample if a first-pass sample is not 
provided (and repeat on a first-pass specimen if abnormal) or make a formal 
arrangement for a first-pass specimen to be provided.
l Measure serum creatinine and estimate the glomerular filtration rate (using 
the method-abbreviated Modification of Diet in Renal Disease four-variable 
equation) annually at the time of ACR estimation.
l Repeat the test if an abnormal ACR is obtained (in the absence of proteinuria 
or UTI) at each of the next two clinic visits but within a maximum of 
3–4 months. Take the result to be confirming microalbuminuria if a further 
specimen (out of two more) is also abnormal (>2.5 mg/mmol for men; 
>3.5 mg/mmol for women).
Box 3. Screening recommendations for kidney damage (NICE, 2014).
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pressure and who are at low overall CV risk 
(Bilous et al, 2009). For hypertensive people, or 
those who have already had a CV event, then 
angiotensin-converting enzyme (ACE) inhibitors 
have been shown to prevent the development of 
severe albuminuria (Heart Outcomes Prevention 
Evaluation Study Investigators, 2000). 
Once people have persistent moderate 
albuminuria then ACE inhibitors in type 1 diabetes 
and angiotensin receptor blockers (ARBs) in type 2 
diabetes reduce progression to severe albuminuria 
and increase regression to normoalbuminuria over 
and above their blood pressure-lowering effect 
(ACE Inhibitors in Diabetic Nephropathy Trialist 
Group, 2001; Parving et al, 2001). However, none 
of these studies were powered to detect any impact 
on rates of ESRD development. There is, however, 
good evidence of benefit of ACE inhibitor therapy 
once people with type 1 diabetes have severe 
albuminuria and a reduced GFR (Lewis et al, 1993). 
In those with type 2 diabetes the effect is smaller 
but still significant and has only been conclusively 
established for ARBs (Brenner et al, 2001; Lewis et 
al, 2001). Meta-analysis has confirmed these benefits 
(Palmer et al, 2015).
The UKPDS showed that many people with 
type 2 diabetes require three or more drugs to 
control their blood pressure to target, so although 
RAS blockade forms the cornerstone of therapy, 
other agents will almost certainly need to be added 
(UKPDS Group, 1998b). 
A high dietary salt intake will reduce the 
effectiveness of RAS blockers so reduction should 
be reiterated for all people taking them. Diuretics 
work synergistically with RAS-blocking agents. 
For people with CKD stage 3 or worse then loop 
diuretics rather than thiazides are indicated. 
Calcium-channel blockers are the next agent 
recommended in the British Hypertension Society 
guidelines, but beta-blockers are also useful in 
people with a history of ischaemic heart disease or 
heart failure (NICE, 2013; Joint British Societies, 
2014). Concerns about their use in people with 
hypoglycaemia unawareness are probably overstated, 
although it is prudent to use cardioselective agents.
Current hypertension guidance suggests a blood 
pressure target of <130/80 mmHg (Joint British 
Societies, 2014), although these targets have been 
called into question recently (Mahmoodi et al, 
2012) and there may be little gain and even possible 
harm in reductions <140/90 mmHg. Control can 
be difficult to achieve without polypharmacy to 
a degree that has intolerable side effects or poses a 
problem for concordance and compliance. However, 
any reduction in blood pressure is of potential 
benefit, so it is critical to negotiate acceptable targets 
with people on an individual basis. A Cochrane 
review has found a reduction in dietary protein 
to be beneficial in terms of slowing nephropathy 
progression (Robertson et al, 2007).
As most people with diabetes and nephropathy 
have macrovascular disease, a small minority 
will have a functional renal artery stenosis. Renal 
blood flow in these people is dependent upon a 
functioning RAS so inhibition using ACE inhibitors 
or ARBs can result in an acute deterioration of 
renal function. For this reason, it is recommended 
that serum creatinine and potassium are checked 
within 2 weeks of initiation of RAS blockade and 
after any increase in dose (NICE, 2013; 2014; Joint 
British Societies, 2014). A rise in serum creatinine 
of >75 µmol/L should raise the possibility of renal 
artery stenosis. Increases less than this are common 
and not usually of clinical significance.
Because people with nephropathy have an 
increased risk of CV disease, cholesterol-lowering 
therapy and low-dose aspirin should be considered 
for all using the newer lifetime CV risk calculator 
which takes into account the presence of CKD 
(Joint British Societies, 2014). In reality, most 
people with diabetic nephropathy will have evidence 
of pre-existing macrovascular complications and 
should be prescribed such therapy for secondary 
Page points
1. Cholesterol-lowering therapy 
and low-dose aspirin should be 
considered for individuals who 
have a 5-year cardiovascular 
disease risk >20% based upon 
the Framingham equation (Joint 
British Societies, 2014).
2. NICE has issued guidelines for 
the management of both type 1 
and type 2 diabetes that include 
advice on diabetic nephropathy.
l Chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate 
[eGFR] <30 mL/min/1.73 m2).
l Rapid loss of GFR (>5 mL/min/1.73 m2/year or >10 mL/min/1.73 m2/5 years).
l Microscopic haematuria.
l Heavy proteinuria (>1 g/day or protein–creatinine ratio >100 mg/mmol)  
– especially if sudden onset or associated with nephrotic syndrome or in  
the absence of retinopathy.
l Features of other systemic disease (e.g. rheumatoid arthritis, systemic lupus or 
cancer).
l Further guidance is available from the Royal College of General Practitioners 
website (www.rcgp.org.uk; accessed 20.03.13).
Box 4. When to refer to secondary care (adapted from Joint Specialty 
Committee on Renal Medicine, 2006).
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prevention anyway.
People with nephropathy are at high risk of 
foot ulceration and many will have established 
retinopathy. It is important that they continue to 
access foot and retinal screening.
The Steno-2 Study (Gaede et al, 2008) of 
multifactorial CV risk intervention in people 
with type 2 diabetes with moderate albuminuria 
at baseline demonstrated long-term benefits on 
mortality, development of nephropathy and 
ESRD, as well as CV complications, including 
myocardial infarction and amputation. The 
treatment included RAS-blocking drugs in all 
participants in the intensively treated group, lipid-
lowering therapy with a target total cholesterol 
<4.5 mmol/L, intensive glycaemic control with a 
target HbA1c level of <48 mmol/mol (<6.5%), low-
dose aspirin, antioxidants (vitamins C and E) and 
lifestyle changes, including stopping smoking, 
weight reduction and increasing exercise. As with 
the DCCT/EDIC and UKPDS, these benefits 
continued beyond the end of the trial. 
NICE has issued guidelines for the management 
of both type 1 and type 2 diabetes that include 
advice on diabetic nephropathy (NICE, 2015a; 
2015b). Moreover, there is guidance for CKD 
generally, which also includes a section on diabetes 
(Joint Specialty Committee on Renal Medicine 
of the Royal College of Physicians and the Renal 
Association, Royal College of General Practitioners, 
2006; NICE, 2014). 
When to refer? 
The Royal College of General Practitioners has 
issued guidance on the indications for referral for 
people with CKD (Joint Specialty Committee 
on Renal Medicine, 2006; Box 4). People with 
chronic, stable renal impairment and well-controlled 
glycaemia and blood pressure probably do not 
need referral even if they are at CKD stage 4. 
However, any person in whom glycaemia or blood 
pressure control is proving difficult and/or who 
has a rapidly declining GFR of >5 mL/min/year or 
>10 mL/min/5 years should be referred as they are 
at risk of requiring renal replacement therapy and 
this needs to be planned early. Similarly those with 
anaemia or calcium and phosphate problems should 
also be referred.
People with type 2 diabetes can also develop 
Narrative
Fred is 59 and has had type 2 diabetes for 6 years. Lately he has struggled with his blood glucose 
control and his HbA1c level has gradually crept up to 81 mmol/mol (9.6%). His current treatment 
is metformin 500 mg three times daily and gliclazide 120 mg twice daily. He weighs 92 kg and 
has a BMI of 29 kg/m2. He works as a taxi driver and does not drink alcohol or smoke. His blood 
pressure is 152/94 mmHg on repeat measurements. His estimated glomerular filtration rate is 
65 mL/min/1.73 m2 and his albumin–creatinine ratio was 5.7 and 7.8 mg/mmol on the last two 
tests. Retinal photography shows minimal background retinopathy. His plasma cholesterol is 
6.2 mmol/L with an estimated low-density lipoprotein cholesterol of 3.6 mmol/L. His only other 
medication is ramipril 5 mg a day. How would you reduce his renal risk?
Discussion 
Fred has retinopathy so his abnormal albumin–creatinine ratio almost certainly means that he has 
established nephropathy. At this stage effective blood pressure control and full renin–angiotensin 
system blockade is critical. He is on a submaximal dose of ramipril so this should be doubled to 
10 mg a day and his plasma creatinine checked within 2 weeks. At the same time he should see the 
dietitian and nurse to see if he can lose weight and to check the salt content of his diet. Remember 
that most dietary salt is hidden in foods such as breads, pizzas and cereals. Fred’s cardiovascular 
risk is >20% over the next 10 years, so he would benefit from a statin but there is no evidence of 
benefit as yet for low-dose aspirin. Improved glycaemic control would help prevent retinopathy 
progression. Insulin use may not be compatible with his job, so the addition of pioglitazone 
(although this can cause weight gain), a glucagon-like peptide-1 receptor agonist or a dipeptidyl 
peptidase-4 inhibitor could be considered (there are differences within each of these classes 
regarding renal restrictions relating to the prescribing of the agents, and so readers are advised to 
familiarise themselves with relevant prescribing information). Although he is not quite on maximal 
metformin and gliclazide, a further increase would be unlikely to achieve his glycaemic target. Fred 
needs to know about his cardiorenal risk and the importance of adherence should be emphasised. 
He may well need support or even counselling to come to terms with his condition.
Box 5. Case example one.
Narrative
Kylie has type 1 diabetes of 15 years’ duration and is 21 years old. At her regular review she reports 
frequent hypoglycaemia, particularly during working hours as a waitress. Her HbA1c level is 
77 mmol/mol (9.2%) and she admits that she finds it hard to take her insulin regularly at work. Her 
blood pressure is 118/74 mmHg and her albumin–creatinine ratio is 2.8 mg/mmol. Kylie is on the oral 
contraceptive pill and should be taking short-acting insulin three times daily and a night-time long-
acting insulin analogue. Her latest retinal photograph shows early background retinopathy. What are 
the priorities of treatment to prevent nephropathy?
Discussion
Improvement of Kylie’s glycaemic control is critical. The Diabetes Control and Complications Trial 
(DCCT) showed that intensive glycaemic control (average achieved HbA1c level of 53 mmol/mol 
[7.0%]) reduced the risk of developing microalbuminuria by >40% (DCCT/ Epidemiology of 
Diabetes Interventions and Complications [EDIC] Research Group, 2003). For retinopathy, the 
benefit was greater the higher the baseline HbA1c, but it is not known if this is true for nephropathy. 
The concern is hypoglycaemia, which is likely to increase as HbA1c improves. Options for Kylie 
include education programmes such as DAFNE (Dose Adjustment For Normal Eating), dietetic 
referral to learn or refresh carbohydrate counting, or an insulin pump. (It should be noted that 
retinopathy can temporarily worsen with improved glycaemia so repeat photography in 6 months 
is recommended.) Latest evidence from renal biopsy studies suggest that retinopathy is a sensitive 
marker of pathological damage in the kidneys (Klein et al, 2005). Therefore, although her albumin–
creatinine ratio is normal, Kylie is at increased risk of nephropathy and needs to know this.
Box 6. Case example two.
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renal disease other than nephropathy and should 
be referred if they show any of the unusual features 
outlined in Box 4. The presence of retinopathy in 
a person with diabetes and albuminuria makes a 
diagnosis of diabetic nephropathy almost certain 
(He et al, 2012).
Psychological aspects
For many people with diabetes, the diagnosis 
of nephropathy and possible renal failure is an 
ominous one. Most will be aware of the implications 
and will show a classic bereavement reaction similar 
to that seen following a diagnosis of cancer or heart 
disease. For these reasons it is important to prepare 
people and their partners, carers and families well in 
advance of the need for renal replacement therapy. 
Many renal units offer pre-end-stage education and 
counselling as part of preparation for dialysis. For 
younger people, live donor kidney transplantation 
may be an option and requires careful and sensitive 
management.
Box 5 and Box 6 provide case examples that 
highlight some of the practical issues related to the 
management of people with diabetic nephropathy. 
Conclusion
Nephropathy is a serious complication of diabetes 
and is associated with significant mortality and 
comorbidity. However, there is a strong evidence 
base for therapies that can prevent development and 
slow its progression. Thirty years ago the median 
time from development of severe albuminuria to 
ESRD was just 7 years (Watkins et al, 1977) – it is 
now closer to 20 years. Moreover, the numbers of 
people requiring renal replacement therapy appear 
to be falling, at least in the US. This is probably the 
result of better overall care in terms of glycaemia 
and blood pressure and CV risk factor management. 
The remaining challenge is to try to prevent people 
developing nephropathy in the first place. n
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“Nephropathy is a 
serious complication 
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is associated with 
significant mortality 
and comorbidity. 
However, there is 
a strong evidence 
base for therapies 
that can prevent 
development and slow 
its progression.”
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1. Ten years after the diagnosis of type 1 
diabetes, what APPROXIMATE percentage 
of people are likely to have pathological 
thickening of the glomerular basement 
membrane? Select ONE option only.
A. <10
B. 33
C. 50
D. 66
E. >90
2. In which ONE of the following situations 
is the finding of microalbuminuria MOST 
LIKELY to represent a false-positive 
result? Select ONE option only.
A. A 21-year-old man with type 1 
diabetes who was admitted with 
diabetic ketoacidosis 10 days 
before the test was taken
B. A 37-year-old woman with type 1 
diabetes who was on day 14 of her 
menstrual cycle when the test was taken 
C. A 42-year-old man with type 2 
diabetes who undertook gentle 
walking exercise for 30 minutes 
immediately before the test
D. A 55-year-old man with type 2 diabetes 
and hypertension who takes regular 
candesartan 16 mg each morning
E. A 78-year-old female with type 2 
diabetes who is taking trimethoprim for 
an intercurrent urinary tract infection
3. Which is the MOST LIKELY source of 
serum creatinine? Select ONE option only.
A. Gastrointestinal tract
B. Kidney
C. Liver
D. Muscle
E. Skin
4. The eGFR calculation is derived 
from the MDRD study. Which ONE 
of the following is NOT included in 
the modification of the original study 
algorithm? Select ONE option only.
A. Age
B. BMI
C. Ethnicity
D. Gender
E. Serum creatinine
5. At which level (mL/min/1.73 m2) is the 
eGFR MOST LIKELY to UNDERESTIMATE 
true glomerular filtration rate? 
Select ONE option only.
A. 21–30
B. 31–40
C. 41–50
D. 51–60
E. 61–70
6. According to the UKPDS study, what 
APPROXIMATE percentage of people 
are likely to have required a renal 
transplant or died from renal failure 
10 years after their diagnosis of type 2 
diabetes? Select ONE option only.
A. 0.5
B. 2.5
C. 5
D. 7.5
E. 10
7. A 73-year-old woman with type 2 diabetes 
has significant diabetic nephropathy. 
She has normocytic anaemia. Which is 
the MOST LIKELY deficiency causing 
her anaemia? Select ONE option only.
A. Aldosterone
B. Erythropoietin
C. Folate
D. Renin
E. Vitamin B12
8. A 62-year-old male smoker with 
type 2 diabetes and diabetic 
nephropathy develops nephrotic 
syndrome. Which of the following 
clinical findings is LEAST expected in 
this situation? Select ONE option only.
A. Hypoalbuminaemia
B. Hypocholesterolaemia
C. Peripheral arterial disease
D. Peripheral oedema
E. Proteinuria
9. A 57-year-old woman with type 2 diabetes 
has a declining eGFR over several years 
and has recently noticed that the tips 
of her fingers are painful. Which of the 
following are the MOST LIKELY expected 
blood results? Select ONE option only.
10. A 51-year-old man with type 2 diabetes 
and hypertension has recently started 
ramipril 2.5 mg once daily. Which of the 
following is the MOST LIKELY indication 
that he has underlying renal artery 
stenosis? Select ONE option only.
A. Decrease in blood pressure 
since starting ramipril
B. No change in blood pressure 
since starting ramipril
C. Increase in blood pressure 
since starting ramipril
D. Increase in serum creatinine 
(>75 µmol/L) since starting ramipril
E. Increase in eGFR (>25 mL/min/1.73 m2) 
since starting ramipril
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Phosphate Calcium
Parathyroid 
hormone
A. Low Low Low
B. Low High Low
C. Normal Normal Normal
D. High Low High 
E. High High High
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